Xcout Intel
Thylacine Biotherapeutics Inc
Thylacine Biotherapeutics Inc. is a privately held biotech company headquartered in Miami Beach, Florida, dedicated to combating infectious diseases. The company develops a drug pipeline addressing both commercial and biothreat indications, including novel antiviral peptides.
Subscribe to see Thylacine Biotherapeutics Inc’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Thylacine Biotherapeutics Inc at a glance
Thylacine Biotherapeutics Inc is a company headquartered in United States. Its most recent funding round raised $476,000 in January 2023. Xcout tracks 10 named people at Thylacine Biotherapeutics Inc, including Daniel Graifman (President).
Thylacine Biotherapeutics Inc leadership
- Daniel GraifmanPresident
- Walter GreenblattChief Financial Officer
- Joan Fusco, PhDChief Development Officer
- Tom Monath, MDChief Medical Officer
- Anne Moscona, MDInventor
- Matteo Porotto, PhDInventor
4 more named people on record for Thylacine Biotherapeutics Inc, with roles, board committees and tenure — see the full roster →
Thylacine Biotherapeutics Inc funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $476,000 | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Thylacine Biotherapeutics Inc competitors
A few of Thylacine Biotherapeutics Inc's closest competitors — see the full list of competitors and alternatives →
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.
Island Pharmaceuticals Ltd is an Australian antiviral drug development company based in Melbourne, Australia, focused on addressing infectious diseases.
Immorta Bio, Inc. is a regenerative medicine and scientific longevity company dedicated to providing innovative health solutions. Headquartered in Miami Beach, Florida, the company develops specialized therapeutics and operates within the biotechnology sector.
Canlab International is a supplier of high-purity research peptides based in Miami Beach, Florida. The company provides specialized research products while noting that its statements have not been evaluated by the U.S. Food and Drug Administration.
Vaxxinity, Inc. is a biotechnology company committed to democratizing healthcare globally through proprietary synthetic peptide immunotherapies, maintaining operations and a headquarters facility in Florida.
Maxwell Biosciences, Inc. is a biotechnology company based in Austin, Texas. It develops biomimetic, peptide-inspired anti-infective drugs designed to act as a synthetic immune system.
Get Thylacine Biotherapeutics Inc's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Thylacine Biotherapeutics Inc in Xcout Intel
- 10 named people with titles, LinkedIn and board committees
- 1 funding round with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access